Literature DB >> 10095294

Australia's notifiable diseases status, 1997. Annual report of the National Notifiable Diseases Surveillance System.

E O'Brien1, R D'Souza, N Gilroy, M Burgess, S Lister, P McIntyre, S Torvaldsen, K Moser, A Milton.   

Abstract

In 1997 there were 89,579 notifications to the National Notifiable Diseases Surveillance System. A notable feature of 1997 was the pertussis outbreak which peaked towards the end of the year and resulted in 10,668 cases being notified. The highest number of notifications received was for hepatitis C (unspecified) with 19,692 notifications; this is the first year for which data have been reported for New South Wales and South Australia for this disease category. The number of measles cases rose after the low number reported in 1996 but is still well below the number reported in the outbreak years of 1993 and 1994. Rubella notifications continued to decline in 1997. Notifications of Haemophilus influenzae type b appeared to have stabilised at a low rate, having declined markedly after introduction of the conjugated vaccine in 1992. The number of cases of campylobacteriosis remained steady after having risen for several years. Notifications of hepatitis A cases rose considerably, much of this being due to one outbreak in New South Wales. The number of cases of salmonellosis rose while shigellosis numbers dropped slightly. Notifications for chlamydial infection and gonococcal infection continued to rise, whilst those for syphilis continued to fall.

Entities:  

Mesh:

Year:  1999        PMID: 10095294

Source DB:  PubMed          Journal:  Commun Dis Intell        ISSN: 0725-3141


  2 in total

1.  Re-vaccination of 421 children with a past history of an adverse vaccine reaction in a special immunisation service.

Authors:  M Gold; H Goodwin; S Botham; M Burgess; M Nash; A Kempe
Journal:  Arch Dis Child       Date:  2000-08       Impact factor: 3.791

2.  Improving the accuracy of Aboriginal and non-Aboriginal disease notification rates using data linkage.

Authors:  Donna B Mak; Rochelle E Watkins
Journal:  BMC Health Serv Res       Date:  2008-05-30       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.